{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:07:19Z","timestamp":1772136439178,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10067-023-06615-7","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T13:54:49Z","timestamp":1684158889000},"page":"2249-2250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-synthetase syndrome and the risk of progressive pulmonary fibrosis: weighting of concomitant anti-Ro\/SSA antibodies"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-1676","authenticated-orcid":false,"given":"David","family":"Bernal-Bello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4189-1046","authenticated-orcid":false,"given":"Jorge","family":"Rodr\u00edguez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6138-7558","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Duarte-Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4486-8365","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Frutos-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"6615_CR1","doi-asserted-by":"publisher","unstructured":"Fu H, Zheng Z, Zhang Z et al (2023) Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-023-06570-3","DOI":"10.1007\/s10067-023-06570-3"},{"key":"6615_CR2","first-page":"S131","volume":"33","author":"M Wodkowski","year":"2015","unstructured":"Wodkowski M, Hudson M, Proudman S et al (2015) Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol 33:S131\u2013S135","journal-title":"Clin Exp Rheumatol"},{"key":"6615_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/mr\/roab118","volume":"32","author":"K Meridor","year":"2022","unstructured":"Meridor K, Sagy I, Molad Y (2022) Anti-Ro\/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis. Mod Rheumatol 32:1086\u20131093. https:\/\/doi.org\/10.1093\/mr\/roab118","journal-title":"Mod Rheumatol"},{"key":"6615_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/kev300","volume":"55","author":"R Gunnarsson","year":"2016","unstructured":"Gunnarsson R, El-Hage F, Aal\u00f8kken TM et al (2016) Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 55:103\u2013108. https:\/\/doi.org\/10.1093\/rheumatology\/kev300","journal-title":"Rheumatology (Oxford)"},{"key":"6615_CR5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","volume":"78","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Pinal-Fernandez I, Kishi T et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78:988\u2013995. https:\/\/doi.org\/10.1136\/annrheumdis-2018-215004","journal-title":"Ann Rheum Dis"},{"key":"6615_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3899\/jrheum.220139","volume":"50","author":"C Lv","year":"2023","unstructured":"Lv C, You H, Xu L et al (2023) Coexistence of anti-Ro52 antibodies in anti-MDA5 antibody-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk. J Rheumatol 50:219\u2013226. https:\/\/doi.org\/10.3899\/jrheum.220139","journal-title":"J Rheumatol"},{"key":"6615_CR7","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","volume":"61","author":"X Gui","year":"2022","unstructured":"Gui X, Shenyun S, Ding H et al (2022) Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology (Oxford) 61:4570\u20134578. https:\/\/doi.org\/10.1093\/rheumatology\/keac090","journal-title":"Rheumatology (Oxford)"},{"key":"6615_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12016-020-08814-5","volume":"60","author":"T Vojinovic","year":"2020","unstructured":"Vojinovic T, Cavazzana I, Ceruti P et al (2020) Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis. Clin Rev Allergy Immunol 60:87\u201394. https:\/\/doi.org\/10.1007\/s12016-020-08814-5","journal-title":"Clin Rev Allergy Immunol"},{"key":"6615_CR9","doi-asserted-by":"publisher","first-page":"106134","DOI":"10.1016\/j.rmed.2020.106134","volume":"172","author":"X Xing","year":"2020","unstructured":"Xing X, Li A, Li C et al (2020) Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med 172:106134. https:\/\/doi.org\/10.1016\/j.rmed.2020.106134","journal-title":"Respir Med"},{"key":"6615_CR10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","volume":"41","author":"I Marie","year":"2012","unstructured":"Marie I, Hatron PY, Dominique S et al (2012) Shortterm and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41:890\u2013899","journal-title":"Semin Arthritis Rheum"},{"key":"6615_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi J, Li S, Yang H et al (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 44:1051\u20131057. https:\/\/doi.org\/10.3899\/jrheum.161480","journal-title":"J Rheumatol"},{"key":"6615_CR12","doi-asserted-by":"publisher","unstructured":"Zhao Y, Zhang C, Su H et al (2023) Predictive factors for progressive fibrosing interstitial lung disease in anti-synthetase syndrome. Int J Rheum Dis. https:\/\/doi.org\/10.1111\/1756-185X.14664","DOI":"10.1111\/1756-185X.14664"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06615-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:11:43Z","timestamp":1689232303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06615-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6615"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06615-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"21 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}